PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23635096-13	2013	Co-administration of candesartan with pioglitazone, which have anti-inflammatory (changes in HMW-ADN and PAI-1) effects and protective effects on organs, could be an effective therapeutic strategy for treating hypertensive patients with type 2 diabetes mellitus.	candesartan	21-32	serpin family E member 1	Homo sapiens	105-110	
23034088-11	2012	CONCLUSIONS: Candesartan improved inflammatory parameters (HMW-ADN and PAI-1) in hypertensive patients with type 2 diabetes mellitus of long duration independent of blood pressure changes.	candesartan	13-24	serpin family E member 1	Homo sapiens	71-76	
21814211-0	2011	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.	candesartan	71-82	serpin family E member 1	Homo sapiens	33-38	
21814211-1	2011	To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome.	candesartan	158-169	serpin family E member 1	Homo sapiens	44-77	
21814211-1	2011	To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome.	candesartan	158-169	serpin family E member 1	Homo sapiens	79-84	
21814211-8	2011	In both groups there was a positive correlation between Ang II and PAI-1 changes (r=0.61, P<0.001 at week 16 for imidapril, and r=0.37, P<0.005 at week 16 for candesartan).	candesartan	165-176	serpin family E member 1	Homo sapiens	67-72	
21179101-7	2011	Both drugs decreased PAI-1 antigen activity after 4 weeks of treatment; subsequently, only the decreasing effect of imidapril was sustained throughout the 12 weeks, whereas candesartan increased PAI-1 activity at week 12 (P<0.05 vs. baseline, P<0.01 vs. imidapril).	candesartan	173-184	serpin family E member 1	Homo sapiens	195-200	
17541328-5	2007	The fibrinolytic balance was significantly different between treatment groups (molar ratio of PAI-1/tPA: candesartan, 3.66 [2.2;] lisinopril, 5.44 [2.6;] P<.05).	candesartan	105-116	serpin family E member 1	Homo sapiens	94-99	
15488878-5	2004	Compared with placebo or losartan, irbesartan and candesartan significantly lowered plasma levels of PAI-1 antigen (P <0.001 by ANOVA) with no differences between the two.	candesartan	50-61	serpin family E member 1	Homo sapiens	101-106